Neal Shore, MD of Carolina Urologic Research Center @UrologyUS on how the ProVent trial might change the AS treatment landscape.…
Neal Shore, MD of Carolina Urologic Research Center @UrologyUS provides insight on current treatment options for men in the phase…
Neal Shore, MD of Carolina Urologic Research Center @UrologyUS discusses the phase 3 provent clinical trial. ____________ Dendreon Pharmaceuticals, a…
Robert Hapke, Katherine E. Beckermann MD/PhD, W. Kimryn Rathmell MD/PhD, and Scott M. Haake MD Vanderbilt-Ingram Cancer Center Vanderbilt University…
Abhishek Tripathi MD Assistant Professor, Section of Hematology Oncology University of Oklahoma Stephenson Cancer Center Oklahoma City, OK presents Immune…
Leigh Ellis Department of Oncologic Pathology Dana-Farber Cancer Institute Harvard Medical School presents Using Epigenetic Therapy to Enhance Immunotherapy Response…
Thai Ho Mayo Clinic Arizona presents Therapeutic targeting of the extracellular matrix in kidney cancer Filmed at the 18th International…
Charles G. Drake MD / PhD Director GU Medical Oncology Co-Director: Immunotherapy Program Associate Director for Clinical Research Professor of…
Aguirre A. de Cubas, Ph.D. Post-Doctoral Fellow WK Rathmell Lab Vanderbilt University Medical School presents DNA Demethylation promotes ERV expression…
Haydn Kissick, Ph.D. Department of UrologyDepartment of Microbiology and Immunology presents The T-cell response to Kidney Cancer Filmed at the…
Arlene Sharpe M.D. Ph.D. Department of Immunology Harvard Medical School presents Discovery of new IO Targets Leveraging CRISPR Filmed at…
Patient-reported ECOG performance status (PS) is lower than oncologist-reported PS and is associated with worse psychosocial outcomes. Cristiane Decat Bergerot,…
Meredith M. Regan,1 Michael B. Atkins,2 Thomas Powles,3 Lillian Werner,4 Charlene Mantia,5 Shuo Yang,6 Jennifer L. Johansen,6 Sumati Rao,6 Kyna…
Chung-Han Lee1, Amishi Y. Shah2, Vicky Makker1, Matthew Taylor3, David Shaffer4, James J. Hsieh5, Allen L. Cohn6, Chris DiSimone7, Alvaro…
Steven P. Rowe, MD, PhD Division of Nuclear Medicine and Molecular Imaging Russell H. Morgan Department of Radiology and Radiological…
I. Alex Bowman, MD Assistant Professor, Division of Hematology/Oncology UT Southwestern Medical Center, Dallas, TX Co-Authors: Marianna Dakanali, Guiyang Hao,…
Haris Zahoor, Akash Sali, Manju Aron, Imran Siddiqui, Bino Varghese, Steven Cen, Xiaomeng Lei, Anishka D’Souza, Austin Fullenkamp, Mihir Desai,…
Zhen J. Wang, MD Professor of Radiology Department of Radiology and Biomedical Imaging University of California, San Francisco discusses Hyperpolarized…
Ivan Pedrosa, MD PhD Professor of Radiology, Urology, Advanced Imaging Research Center and Biomedical Engineering University of Texas Southwestern, Dallas,…
Allan Pantuck, MD, MS, FACS Professor and Vice Chair, Urology Institute of Urologic Oncology David Geffen School of Medicine at…
Martin H. Voss1, Arun Azad2, Aaron R. Hansen3, Jhanelle E. Gray4, Sarah J. Welsh5, Xuyang Song6, Ikbel Achour6, Heping Hu6,…
Ritesh Kotecha1, Ronan Flippot2, Sujata Patil1, Taylor Nortman1, Annalisa Guida2, Ashley Foster1, Bernard Escudier2, Robert Motzer1, Laurence Albiges2, Martin Voss1…
Viraj Master MD PhD FACS Professor Fray F. Marshall Chair in Urological Research Department of Urology Director of Integrative Oncology…
Elad Sharon, MD, MPH Senior Investigator/Medical Officer Cancer Therapy Evaluation Program Division of Cancer Therapy & Diagnosis National Cancer Institute…
Tian Zhang, MD, MHS discusses Aiming to personalize immunotherapy with existing and emerging biomarkers at the 18th International Kidney Cancer…
André P. Fay, MD, PhD Professor, PUCRS School of Medicine Chief, Medical Oncology Department – OncoclÃnicas/HSL-PUCRS Visiting Scientist at Dana-Farber…
Walter Stadler, MD FACP Dean for Clinical Research Deputy Director Comprehensive Cancer Center University of Chicago discusses Favorable Risk Renal…
Michael R. Harrison, MD Associate Professor of Medicine Duke Cancer Institute discusses Active Surveillance for Favorable Risk mRCC at the…
Deborah Maskens MA MSM International Kidney Cancer Coalition discusses Unmet Patient Needs: Results from IKCC Global Survey at the 18th…
David Braun, MD, PhD DF/HCC Kidney Cancer SPORE Harvard Medical School discusses Understanding CD8+ T Cell Function and Specificity in…
Toni K. Choueiri, MD On Behalf of DF/HCC SPORE leadership PI: McDermott and Kaelin gives an overview of the Dana-Farber/Harvard…
Srinivas Malladi, Ph.D. Harold C. Simmons Comprehensive Cancer Center, Department of Pathology University of Texas Southwestern Medical Center, Dallas, TX…
James Brugarolas, M.D., Ph.D. Director, Kidney Cancer Program Principal Investigator, Kidney Cancer SPORE Sherry Wigley Crow Endowed Chair in Cancer…
Mark H. Michalski MD Executive Director, Center for Clinical Data Science Massachusetts General Hospital/Brigham and Women’s Hospital discusses How Artificial…
W. Kimryn Rathmell, MD, PhD Professor of Medicine and Biochemistry; Director, Division of Hematology and Oncology Vanderbilt University Medical Center…
Pavlos Msaouel, MD, PhD Assistant Professor Genitourinary Medical Oncology The University of Texas MD Anderson Cancer Center discusses Changing Paradigms…
Javid J. Moslehi, M.D. Associate Professor of Medicine Director, Cardio-Oncology Program Co-Director, Vanderbilt Program for Optimizing Immuno-oNcology Therapy (V-POINT) Vanderbilt…
Bianca D. Santomasso MD, PhD Assistant Professor, Department of Neurology Memorial Sloan Kettering Cancer Center discusses Current Management Strategies for…
Yinghong (Mimi) Wang, MD, PhD Director of Medication-Induced Colitis and Enteritis Director of Fecal Microbiota Transplantation Department of Gastroenterology, Hepatology…
Raja-Elie E. Abdulnour, M.D. Assistant Professor of Medicine Pulmonary and Critical Care Medicine DFCI / BWH discusses Current Management Strategies…
Kerry Reynolds, MD Clinical Director, Inpatient Oncology UnitsDirector, Severe Immunotherapy Complications ServiceMassachusetts General Hospital, Boston, MA discusses Establishing an Immune…
Gopal N. Gupta, MD, FACS Associate Professor Departments of Urology, Surgery and Radiology Fellowship Director, Society of Urologic Oncology Cardinal…
Raj Ayyagari M.D. Assistant Professor of Radiology Department of Radiology Yale University School of Medicine discusses What is Optimal for…
Jose A. Karam, MD, FACS Associate Professor Departments of Urology and Translational Molecular Pathology MD Anderson discusses the Optimal Management…
Rod J Ellis, M.D. FACRO Professor and Chair Radiation Oncology Penn State University Milton Hershey Medical Center Hershey Pennsylvania discusses…
Stenio de Cássio Zequi, MD, MSc, PhD Head of Referral Center for Urological Tumors Robotic and HIFU Programs at AC…
Alexander Kutikov, MD, FACS Professor and Chief, Urologic Oncology Fox Chase Cancer Center, Philadelphia, PA discusses Treatment of the Cystic…
William C Huang, MD Associate Professor and Vice Chair of Urology NYU School of Medicine Chief of Urology and Co-Director…
Steven C. Campbell, MD, PhD Professor Surgery, Vice Chair, Program Director Section of Urologic Oncology, Department of Urology Glickman Urological…
Sasan Setoodeh, MD Genitourinary Pathology Fellow University of Texas Southwestern, Dallas, Texas discusses the Effects of Immune Checkpoint Inhibitors on…
Neil Mendhiratta MD, MS UCLA David Geffen School of Medicine discusses the Identification of Oncocytic Neoplasms with Cyclin D1 Immunohistochemistry…
Gennady Bratslavsky, M.D. Professor and Chairman Department of Urology Upstate Medical University Syracuse, NY discusses Surgical Insights For Variant Histology…
Matt Campbell MD Assistant Professor GU Medical Oncology discusses The Argument for Front Line TKI based treatment for non-clear cell…
Primo N. Lara, Jr., MD Director, UC Davis Comprehensive Cancer Center Professor of Medicine and Executive Associate Dean UC Davis…
Eric C. Kauffman, MD Department of Urology, Roswell Park Comprehensive Cancer Center, Buffalo NY Kidney Cancer Association Meeting, Miami FL…
Nizar M. Tannir, MD, FACP Ransom Horne, Jr. Professor for Cancer Research Professor and Chair ad interim Department of Genitourinary…
Ying-Bei Chen, MD, PhD Associate Attending Pathologist Memorial Sloan Kettering Cancer Center discusses the Importance of Tumor Profiling for Rare…
Michelle Hirsch, MD, PhD Associate Professor of Pathology Chief, Genitourinary Pathology Service Brigham and Women’s Hospital Harvard Medical School discusses…
Oncoceutics, Inc. announced that results from the second and third cohort of the Phase II trial for patients with recurrent…
V.K. Gadi, MD of @SeattleCCA answers commonly asked questions of the AVIATOR study and shares how it will affect future…
V.K. Gadi, MD of @SeattleCCA discusses the AVIATOR study for HER2-positive metastatic breast cancer. __________ Read here:Â https://www.seattlecca.org/clinical-trials/breast-cancer-nct03414658
Earn CME: https://www.naccme.com/program/19-gdugi-1 In this webcast from the ‘Metastatic Colorectal Cancer: An individualized Approach to Optimal Treatment Selection and Adverse…
Earn CME: https://naccme.com/program/19-gdugi-1 In this webcast from the ‘Metastatic Colorectal Cancer: An individualized Approach to Optimal Treatment Selection and Adverse…
Earn CME: https://naccme.com/program/19-gdugi-4 In this webcast from the ‘Exploring the Evolving Role of Immunotherapy in Advanced Hepatocellular Carcinoma: Considerations for…
Earn CME: https://naccme.com/program/19-gdugi-2 In this webcast from the ‘Making Progress in Advanced Hepatocellular Carcinoma with Targeted Agents: Considerations for Therapeutic…
Earn CME: https://naccme.com/program/19-gdugi-4 In this webcast from the ‘Exploring the Evolving Role of Immunotherapy in Advanced Hepatocellular Carcinoma: Considerations for…
Giorgio Scagliotti, MD @giorgioscaglio3 discusses the IASLC. _________ Read here:Â https://www.oncologytube.com/video/iaslc-open-comment-period-on-multidisciplinary-recommendations-for-pathologic-assessment-of-lung-cancer-resection-specimens-following-neoadjuvant-therapy-
Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that data from the clinical program evaluating its lead candidate melflufen in multiple…
Heidi Gray, MD @heidigraydrezn5 of @SeattleCCA @UWashOBGYN discusses the phase I/II study of ruxolitinib with front-line neoadjuvant and post-surgical therapy…
-Recommended and maximum tolerated dose defined as 1.5 mg/kg for further study–Expansion cohort in head and neck squamous cell carcinoma…
Jianjun Zhang, MD of @MDAndersonNews discusses immune and circulating tumor DNA profiling following radiation treatment for oligometastatic NSCLC. How will…
Richard Sainson, PhD @rcasainson of @kymabltd answers KY1044, targets ICOS increasing cytotoxic to regulatory T cells ratio: how does this…
Richard Sainson, PhD @rcasainson of @KymabLtd explains KY1044, targets ICOS increasing cytotoxic to regulatory T cells ratio: what mechanism of…
Jianjun Zhang, MD of @MDAndersonNews discusses immune and circulating tumor DNA profiling following radiation treatment for oligometastatic NSCLC.
Richard Sainson, PhD @rcasainson of @kymabltd shares Kymab’s new findings for KY1044 presented at the #CICON2019 annual meeting.
Ayman A. Saad, MD of @OSUCCC_James answers commonly asked questions regarding the @NCCN guidelines debut to manage complications and actually…
– Results Demonstrated Statistically Significant Improvement in Progression-Free Survival – – Data to be Submitted for Presentation at an Upcoming…
Ayman A. Saad, MD of @OSUCCC_James discusses the @NCCN guidelines debut to manage complications and actually improve readiness for stem…
Syndax Pharmaceuticals, Inc. (“Syndax,” the “Company” or “we”) (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of…
At the Icahn School of Medicine at Mount Sinai, the Human Immune Monitoring Center (HIMC) will use state-of – the-art…
— First clinical data from Phase 1 study of MGTA-145 show successful mobilization of target number of stem cells in…
Douglas G. McNeel, MD of @UWCarbone discusses the phase II trial of a DNA vaccine encoding in patients with nonmetastatic,…
— MAVIS Study Identifies Most Responsive Patient Subpopulations, Supporting the Continued Study of Adjuvant Treatment in Localized Melanoma Patients –…
Address to Japan Society of Clinical Oncology focuseson opportunities to expand benefits to more patients Accomplished surgeon-scientist joined Roswell Park…
– Target Enrollment of 450 Achieved Early Due to High Demand – – Topline Results Expected in 2023 – Dendreon…
Douglas G. McNeel, MD of @UWCarbone discusses the phase II trial of a DNA vaccine encoding in patients with nonmetastatic,…
National Comprehensive Cancer Network expands resources to meet growing utilization of cell-based cancer treatments. Today, the National Comprehensive Cancer Network® (NCCN®)…
Katherine Clifton @katherineclift4 of @WUSTL answers a common question regarding using an anti-EGFR resistance mechanism: are these gene fusions targetable?…
Katherine Clifton, MD @katherineclift4 of @WUSTL discusses actionable fusions as an anti-EGFR resistance mechanism. __________ Read here:Â https://ascopubs.org/doi/10.1200/PO.19.00141
A comparison of the Pinktober and Movember movements reveals that reach and engagement do not always lead people to research…
Studies show that proton therapy compared to traditional radiation increases overall survival in patients with inoperable liver cancer and recognizes…
Nicklas Oscarsson of @goteborgsuni on how oxygen in hyperbaric chamber provides relief after radiotherapy affects clinicians and treatment today. ________…
Company Commences First-in-Human Study at Multiple Academic Sites in United States Oct. 29, 2019 /PRNewswire/ — Linnaeus Therapeutics, Inc. (Linnaeus),…
Nicklas Oscarsson of @goteborgsuni answers frequently asked questions regarding oxygen in hyperbaric chamber provides relief after radiotherapy. __________ Hyperbaric oxygen…
Nicklas Oscarsson of @goteborgsuni explains oxygen in hyperbaric chamber provides relief after radiotherapy. ___________ Hyperbaric oxygen therapy (HBOT) in the…
EU approval based on JAVELIN Renal 101 trial results demonstrating significant improvement in progression-free survival with BAVENCIO in combination with…
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (“Actinium”) today announced key interim findings from the pivotal Phase 3 SIERRA trial of…
Evidence from the lead program showed that glucocorticoids promote the growth of prostate tumor cells, stimulate androgen-regulated gene expression and…
Greg Delgoffe, PhD @delgoffelab of @PittTweet explains how the dual-function virus designed to killing tumors is affecting clinicians today. ________…
Greg Delgoffe, PhD @delgoffelab of @PittTweet explains the dual-function virus designed to killing tumors and helping immune cells. __________ Viruses…
Steven Mansoor, MD @mansoor_steven of @OHSUSOM describes what is next and how this protein associated with many disease is visualized…
Steven Mansoor, MD @mansoor_steven of @OHSUSOM answers common questions involving a protein associated with many disease is visualized for the…
Steven Mansoor, MD @mansoor_steven of @OHSUSOM explains a protein associated with many disease is visualized for the first time. ___________…
New drugs can be motivated by understanding how receptors of P2X7 proteins function. Scientists first noticed how a protein associated…
Hyperbaric oxygen therapy (HBOT) in the pelvic region, a study shows, can relieve self-reported symptoms and side effects of radiotherapy…
Bradley E. Bernstein, MD @BradEBernstein @willflavahan of @MassGeneralNews answers how this affects clinicians on the cause of drug resistance found…
Most cases of gastrointestinal stromal tumor (GIST), a form of soft tissue cancer (sarcoma), are caused by gene mutations that…
Bradley E. Bernstein, MD @BradEBernstein @willflavahan of @MassGeneralNews answers commonly asked questions on the cause of drug resistance found in a form…
Bradley E. Bernstein, MD @BradEBernstein @willflavahan of @MassGeneralNews explains the cause of drug resistance found in a form of intestinal tumor. ___________…
Alena Gros of @VHIO answers commonly asked questions regarding the development of cell therapies for non-responders to current immunotherapies: can…
Alena Gros of @VHIO explains driving the development of cell therapies for non-responders to current immunotherapies. __________ Research conducted by…
Research conducted by VHIO’s Alena Gros suggests a modern, less intrusive approach to detecting killer T lymphocytes in patients with…
Peter O’Donnell, MD of @UChicagoMed provides results from biomarkers in patients with locally advanced metastatic urothelial carcinoma treated with durvalumab…
The International Association for the Study of Lung Cancer today announces an open comment period for the “IASLC Multidisciplinary Recommendations…
Cancer center recognized for following best practices in field Designated centers demonstrate best practices outlined by NCCN, ACR Roswell Park’s…
Peter O’Donnell, MD of @UChicagoMed explains biomarkers in patients with locally advanced metastatic urothelial carcinoma treated with durvalumab in phase…
A research study published in Neoplasia, led by lead researcher Nallasivam Palanisamy, Ph.D., associate researcher at the Vattikuti Urology Institute…
Kristin Campbell of @UBCnews shares exercise guidelines for cancer survivors. ________ There is growing evidence that exercise is a significant…
Kristin Campbell of @UBCnews explains exercise guidelines for cancer survivors limitations and safety concerns. __________ There is growing evidence that…
There is growing evidence that exercise is a significant part of recovery for the increasing number of cancer survivors worldwide.…
Akash J. Patel of @bcmhouston answers meningioma molecular profiling reliably predicts tumor recurrence: how does this help us? ________ Read…
Akash J. Patel of @bcmhouston explains meningioma molecular profiling reliably predicts tumor recurrence. __________ Read here: https://www.eurekalert.org/pub_releases/2019-10/bcom-mmp100719.php
Nallasivam Palanisamy, Ph.D. @NallasivamPala4 of @HenryFordNews highlights select biomarkers in patients with prostate cancer and what is next on the…
Nallasivam Palanisamy, Ph.D. @NallasivamPala4 of @HenryFordNews explains a unique biomarker can be detected in the urine samples of prostate cancer…
Nallasivam Palanisamy, Ph.D. @NallasivamPala4 of @HenryFordNews explains a biomarker in urine may offer noninvasive detection of prostate cancer. __________ A…
Carol DeSantis, MPH @caroldesantis6 of @AmericanCancer provides information on trends in breast cancer death rates.
Carol DeSantis, MPH @caroldesantis6 of @AmericanCancer explains breast cancer trends in the U.S.
Emily Bernstein, PhD of @IcahnMountSinai answers neuroblastoma in older children: what happens when you have an ATRX deletion?
Emily Bernstein, PhD of @IcahnMountSinai explains neuroblastoma in older children & adolescents harboring deletions within a gene called ATRX may…
Courtney Williams, MPH @cphilwil of @ONealCancerUAB explains findings in a new study that results in lower costs and how this…
James Suliburk, MD @jsuliburk of @bcmhouston answers how far away is this technology from being used in clinical practice? ___________…
James Suliburk, MD @jsuliburk of @bcmhouston explains new tests for thyroid cancer could prevent unnecessary surgery. ___________ Read here:Â https://www.eurekalert.org/pub_releases/2019-10/uota-ntf100219.php
Courtney Williams, MPH @cphilwil of @ONealCancerUAB explains findings in a new study that results in lower costs for patients with…
Amanda Haymond of @GeorgeMasonNews @GMU_COS explains a new discovery that includes protein painting technology and enables scientists to make discoveries…
Zhibo Ma, PhD of @salkinstitute explains mapping normal breast development to try and better understand cancer. __________ Breast cancer is…
Zhibo Ma, PhD of @salkinstitute explains how this affects treatment and clinicians today. __________ Breast cancer is one of the…
Zhibo Ma, PhD of @salkinstitute answers common questions asked by colleagues regarding measuring chromatin accessibility changes in breast cancer. ________…
Viruses designed to kill cancer cells are already used to treat one skin cancer and are commonly studied in other…
Breast cancer is one of the most common cancers, and some types are among the hardest to treat. The different…
Curtis McCloskey, PhD of @ottawahospital explains how this affects treatment and clinicians today. __________ A laboratory study published in Clinical…
Curtis McCloskey, PhD of @ottawahospital provides insight on a possible new frontier for preventing ovarian cancer. ____________ A laboratory study published…
A laboratory study published in Clinical Cancer Research provides a new perspective on how ovarian cancer is developed and suggests…
Lee P. Richman, MD, Andrew J. Rech, MD and Robert H. Vonderheide, MD of @PennMedicine answer how it is different…
Lee P. Richman, MD, Andrew J. Rech, MD and Robert H. Vonderheide, MD of @PennMedicine discuss an algorithm personalizes which…
When tumor cells expand, tens of thousands of genetic mutations are often spawned. It’s like finding a few needles in…
– Data from pivotal study demonstrate safety and efficacy regardless of prior gastrectomy in previously treated patients with metastatic gastric…
Ajai Chari, MD of @MountSinaiNYC answers how the phase 2 PLEIADES study affects treatment and clinicians today. ____________ About the…
Ajai Chari, MD of @MountSinaiNYC explains a common question asked by colleagues regarding the PLEIADES study: how long do you…
Ajai Chari, MD of @MountSinaiNYC discusses the phase 2 PLEIADES study. _________ About the PLEIADES Trial2Â The non-randomized, open-label, parallel assignment…
Scott Kopetz, MD @skopetz of @MDAndersonNews discusses what’s next for the phase 3 BEACON trial in colorectal cancer. __________ Pfizer…
Scott Kopetz, MD @skopetz of @MDAndersonNews explains the phase 3 BEACON CRC trial. ______ Pfizer Inc. (NYSE: PFE) today announced…
Andrew Krivoshik, MD of @AstellasUS explains insights on EV-103 enfortumab vedotin plus pembrolizumab that was presented at ESMO. #ESMO2019
Andrew Krivoshik, MD of @AstellasUS discusses the EV_103 phase I trial in locally advanced and first- and second-line metastatic urothelial…
GRACE is very excited to bring to you this new program on supportive care in cancer treatment.Arjun Gupta, MD, one…
Suresh S. Ramalingam, MD @RamalingamMD of @WinshipAtEmory illustrates the next step in the phase III FLAURA trial in NSCLC. ________…
Suresh S. Ramalingam, MD @RamalingamMD of @WinshipAtEmory illustrates the next step in the phase III FLAURA trial in NSCLC. ________…
Suresh S. Ramalingam, MD @RamalingamMD of @WinshipAtEmory illustrates the next step in the phase III FLAURA trial in NSCLC. ________…
Sarah Osman of @Queens_Belfast explains the standardized technique is using CT scans to assess and predict prostate cancers in patients.…
Sarah Osman of @Queens_Belfast provides insight on research that found a new way to predict the future behavior of prostate…
Sarah Osman of @Queens_Belfast provides insight on research that found a new way to predict the future behavior of prostate…
Xiao-Ou Shu, MD of @VUMChealth explains how oncologists should treat male breast cancer patients and how it will affect clinicians.…
Valérie Gabarre @valeriegabarre of @OSEIMMUNO discusses the ATALANTE-1 trial and the TEDOPaM study presented by OSE Immunotherapeutics at #ESMO19. __________…
Research from the UAB’s O’Neal Comprehensive Cancer Center finds that patients treated outside the recommendations of the NCCN Guidelines had…
Xiao-Ou Shu, MD of @VUMChealth explains that in a recent study, men have a higher mortality rate than women due…
Researchers from Queen’s University Belfast have discovered a new way to predict the aggressiveness and future behaviour of prostate cancers.…
Once breast cancer spreads to bone, treatment becomes nearly impossible. Breast cancer cells can lie dormant in the bone, often…
Patients with mesothelioma may gain similar benefit from immunotherapy as chemotherapy, and good responders may provide important clues to novel…
The investigational drug selpercatinib may benefit patients with lung cancer whose tumors have alterations in the RET gene, according to preliminary results from a…
Men may be more likely than women to die after being diagnosed with breast cancer, particularly during the first 5…
Ellen J. Kim, MD of @PennMedicine includes observations found in the PROVe Study. #EORTC19 _________ Dr. Ellen J. Kim, UPENN,…
Ellen J. Kim, MD of @PennMedicine addresses questions asked by colleagues including: how long are patients on therapy in the…
Ellen J. Kim, MD of @PennMedicine explains the PROVe Study on efficacy and quality of life (QoL) in patients with…
Chung-Han Lee, MD @ChungHanLee3 of @sloan_kettering answers how it affects clinicians and what is to come in kidney cancer. _______…
Chung-Han Lee, MD @ChungHanLee3 of @sloan_kettering explains questions asked by his colleagues: was the improvement in progression-free survival clinically meaningful?…
Chung-Han Lee, MD @ChungHanLee3 of @sloan_kettering discusses data from randomized #ENTRATA Study in patients with advanced RCC. __________ Data shared…
BOSTON–(BUSINESS WIRE)–Oct. 3, 2019– Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking…
BOSTON–(BUSINESS WIRE)–Oct. 3, 2019– Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking…
(WASHINGTON, October 3, 2019) — Yesterday, ASH President Roy Silverstein, MD, of the Medical College of Wisconsin asked members of the United…
Shaji Kumar, MD of Mayo Clinic explains how patient volumes associated with longer survival in MM will affect clinicians and…
Shaji Kumar, MD of Mayo Clinic explains a new study that supports higher patient volumes are associated with longer survival…
Hypertension with ibrutinib more common than previously reported; this study is first to show association between cancer drug-related hypertension and…
An international panel of experts will identify the best approaches to implement genetic testing for men with prostate cancer  …
Ramaswamy Govindan, MD of Siteman Cancer Center explains the phase I KRAS inhibitor that is well tolerated by patients with…
Ramaswamy Govindan, MD of Siteman Cancer Center answers multiple questions regarding the phase I KRAS inhibitor well tolerated by patients…
Peter Voorhees, MD of Levine Cancer Institute addresses phase 2 GRIFFIN study affecting clinicians and treatment today. _______ The Janssen…
Peter Voorhees, MD of Levine Cancer Institute answers questions received from the audience at IMW 2019 regarding the phase 2…
Peter Voorhees, MD of Levine Cancer Institute answers commonly asked questions by colleagues regarding the phase 2 GRIFFIN study: should…
Peter Voorhees, MD of Levine Cancer Institute explains how the phase 2 GRIFFIN study shows a high response rate in…
COG study shows treatment can be reduced without compromising outcomes Study shows therapy can be reduced in some neuroblastoma patients…
Ashley T. Freeman, MD of BC Cancer explains how the idea that higher patient volumes are associated with longer survival…
Data published today in the New England Journal of Medicine showed that patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with…
September 28, 2019 Â Data shared today in oral presentation at ESMO Congress 2019 show telaglenastat doubles median progression-free survival…
Results from the second interim analysis of the Phase 3 SPARTAN study featured in an oral presentation at ESMO 2019…
Ashley T. Freeman, MD of BC Cancer explains commonly asked questions by colleagues: why do myeloma patients seem to do…
Ashley T. Freeman, MD of BC Cancer provides insight on a study in JNCCN that supports the idea that higher…
Analyses from the Phase III JAVELIN Renal 101 study support efficacy of BAVENCIO plus axitinib across multiple subgroups of patients…
Anurag Singh, MD of Roswell Park explains what’s next in research. ______ Roswell Park researchers present findings at ASTRO Annual…
NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) today announced detailed results from the interim analysis of the Phase 3 BEACON CRC…
Anurag Singh, MD of Roswell Park explains a commonly asked question by colleagues: why is there no benefit to cancer…
Michael Buckstein, MD of Mount Sinai answers commonly asked questions by his colleagues: are you overtreating the patients? What is…
Anurag Singh, MD of Roswell Park reveals that patients with some cancers who have taken baby aspirin can improve overall…
Michael Buckstein, MD of Mount Sinai explains the Phase II trial using combination of TACE and SBRT for unresectable single…
William Smith, MD of Mount Sinai addresses the next steps in radiation therapy on the objective response and outcomes in…
William Smith, MD of Mount Sinai explains how this affects clinicians today? _______ Among patients with unresectable hepatocellular carcinoma who…
William Smith, MD of Mount Sinai answers multiple questions received from colleagues, including: when did patients receive radiation relevant to…
William Smith, MD of Mount Sinai describes the effect of radiation therapy on the objective response and outcomes with nivolumab…
Finding May Explain Why Promising Drugs Work – And When They Won’t   CHARLOTTESVILLE, Va., Sept. 26, 2019 – A…
A recent analysis from Canada found that information on health-related quality of life is often not collected for investigational cancer…
With Breast Cancer Awareness Month Approaching, Cedars-Sinai Experts Discuss New Treatment Options for Early-Stage, Low-Risk Breast Cancer Patients LOS ANGELES…
TORONTO, CANADA / ACCESSWIRE / September 24, 2019 / Soricimed Biopharma Inc. (“Soricimed”), a clinical-stage pharmaceutical company developing first-in-class, targeted cancer therapeutics, today…
GRACE is very excited to bring to you this new program on supportive care in cancer treatment. Arjun Gupta, MD,…
– Opinion based on Phase III data showing combination lowered risk of disease progression or death by 31% and improved…
Gregory Senofsky, MD of UCLA Health explains the standard conversion rate form lumpectomy to mastectomy. ______ FINDINGS Breast cancer surgeons…
Gregory Senofsky, MD of UCLA Health addresses how reducing the need for second surgery after lumpectomy will affect clinicians today…
A majority of patients with cancer don’t understand critical features of the genomic test results they receive when participating in…
Gregory Senofsky, MD of UCLA Health answers a question often asked by colleagues. ______ FINDINGS Breast cancer surgeons performing lumpectomies…
Jonathan Goldman, MD of UCLA Health explains the full trial design of the CASPIAN trial. ______ In the Phase III…
Jonathan Goldman, MD of UCLA Health describes advances in SCLC. _______ In the Phase III CASPIAN trial IMFINZI at a…
Jonathan Goldman, MD of UCLA Health answers on the CASPIAN trial: is this practice changing? _______ In the Phase III…
Jonathan Goldman, MD explains IMFINZI is the first immunotherapy to show both significant survival benefit and improved, durable responses in…
Gregory Senofsky, MD of UCLA Health explains the intraoperative teamwork that greatly reduces the need for second surgery after lumpectomy.…
Sudha Amarnath, MD of Cleveland Clinic discusses how this will affect treatment and clinicians today. _____ Preoperative pelvic radiation (XRT),…
Sudha Amarnath, MD of Cleveland Clinic answers: Is this truly safe? Are these outcomes real? _____ Preoperative pelvic radiation (XRT),…
Sudha Amarnath, MD of Cleveland Clinic discusses toxicity and efficacy outcomes of preoperative pelvic radiation therapy in patients with inflammatory…
New multi-pronged strategy for treating advanced breast cancer earns Breakthrough Award Multifaceted approach combines 3 complementary immunotherapy strategies Two clinical…
Kailin Yang, MD of Cleveland Clinic answers how this will affect clinicians today and questions asked by his colleagues. _______…
Kailin Yang, MD of Cleveland Clinic discusses targeting metabolic reprogramming to radiosensitize glioblastoma stem cells. _________ Inhibiting two critical steps…
Challenges and Pathways to Coverage, with Christine Cambareri, PharmD, BCPS, BCOP. For more, please visit http://cancerGRACE.org/. To join the conversation,…
For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Drs. Jack West, Charu Aggarwal, and Benjamin Levy recently gathered to review top discussion points for Lung Cancer from ASCO…
Drs. Jack West, Charu Aggarwal, and Benjamin Levy recently gathered to review top discussion points for Lung Cancer from ASCO…
Drs. Jack West, Charu Aggarwal, and Benjamin Levy recently gathered to review top discussion points for Lung Cancer from ASCO…
CancerGRACE is devoted to giving you the most up to date information about cancer and cancer treatment. In our ongoing…
CancerGRACE is devoted to giving you the most up to date information about cancer and cancer treatment. In our ongoing…
Drs. Jack West, Charu Aggarwal, and Benjamin Levy recently gathered to review top discussion points for Lung Cancer from ASCO…
Mohammad Jahanzeb, MD shares data presented at WCLC 2019 that he found interesting.
Mohammed Jahanzeb, MD describes what he would like to see next in NSCLC research.
Nearly 14,000 women will die from ovarian cancer in 2019. Now, new research has found that women who use IUDs…
Mohammed Jahanzeb, MD explains the design of the study examining real-world treatment patterns and outcomes in U.S. ALK+ NSCLC patients…
Mohammed Jahanzeb, MD on how this data will affect clinicians today.
Mohammed Jahanzeb, MD answers questions asked by his colleagues.
– Results from ENTRATA Phase 2 trial of telaglenastat in patients with advanced renal cell carcinoma (RCC) accepted as Late-Breaking…
First Phase 3 Study Combining KYPROLIS and DARZALEX, Two Critical Mechanisms of Action in Treatment of Multiple Myeloma  THOUSAND…
Shauna Campbell, MD of Cleveland Clinic shares three nomograms that were presented on salvage radiotherapy. _____ The integration of prostate-specific…
-Â DKN-01 Monotherapy Patient with an Ongoing Complete Response -Â Enhanced PFS in patients with Wnt Activating Mutations and DKK1-high Tumors CAMBRIDGE,…
New research adds to accumulating evidence of benefit for patients treated at high-volume facilities or by high-volume providers. PLYMOUTH MEETING,…
Roswell Park researchers present findings at ASTRO Annual Meeting Aspirin improved overall survival for patients with head/neck, lung cancers Patients…
Shauna Campbell, MD of Cleveland Clinic answers a question received from colleagues: how does it differ from previously published nomograms?…
Shauna Campbell, MD of Cleveland Clinic explains the impact of post-prostatectomy prostate specific antigen (PSA) kinetics on outcomes of salvage…